摘要
目的探讨DNA-PKcs蛋白表达与云南宣威、富源肺腺癌分期及病理分化程度的关系,以期为判断预后、制定合理治疗计划提供依据。方法采用免疫组化S-P法检测64例入选的云南宣威、富源肺腺癌组织中DNA-PKcs蛋白的表达情况,并行统计学处理。结果DNA-PKcs的表达强弱与宣威、富源两地域无关,与临床早(Ⅰa~Ⅱa)晚(Ⅲa~Ⅳ)分期有关(P=0.006,<0.01);与组织高、中、低分化程度有关(P=0.018,<0.05);同期还检测到20例肺腺癌组织中DNA-PKcs的表达与其相对应的癌旁正常组织相比,差异有非常显著性(P=0.0076,<0.01)。结论在云南宣威、富源肺腺癌组织中DNA-PKcs均呈阳性表达,且临床分期越晚、病理分化程度越低,其表达越强,预示DNA-PKcs可能成为云南宣威、富源肺腺癌诊治和预后的一个生物标记物。
Objective To investigate the relationship between expression of DNA-PKcs protein and staging system and pathology of lung adenocarcinoma,and to propose the guideline for diagnosis and treatment.Methods The expression of DNA-PKcs in 64 cases with lung adenocarcinoma was Results Analyzing the expression of DNA-PKcs protein of lung determined by immunohistochemical technique. adenocarcinoma tissue,there was no difference between that in Xuanwei and Fuyuan;but obvious differences in stages Ⅰa- Ⅱa and Ⅲa-Ⅳ (P=0.006),and in pathological grand of cell differentiation (P=-0.018);We also found there was obvious difference between lung adenocarcinoma tissue and lung normal tissue ( P=- 0.0076 ).Conclusion The latter clinical staging and the lower pathological grand are,the higher expression of DNA PKcs is.The expression of DNA-PKcs protein can be regarded as a tumor marker and an index ofproguosis in lung adenocarcinoma occurring in Xuanwei and Fuyuan Counties in Yunnan.
出处
《云南医药》
CAS
2009年第4期407-410,共4页
Medicine and Pharmacy of Yunnan
关键词
DNA依赖蛋白激酶
肺腺癌
免疫组化
病理
DNA-PKcs protein
Lung adenocarcinoma
Immunohistochemistry
Pathology